Retrospective Study on the Effects of Long-Term Use of Methylprednisolone Acetate on the Blood Work of 25 Cats

Sohn, Joanne J.; Gruber, Theresa; Brown, Gaylord M.

doi:10.5326/jaaha-ms-6783

Cited by 4 publications

(7 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One study evaluated long‐term effects of glucocorticoids in asthmatic cats and found adverse effects such as polyuria and polydipsia, diabetes mellitus and fungal infection in four of 34 cats 27 . A study evaluating long‐term safety (at least three years) of methylprednisolone in 25 cats detected an increase of triglycerides, amylase and monocytes, yet changes remained within the reference interval 87 …”

Section: Resultsmentioning

confidence: 99%

“…27 A study evaluating long-term safety (at least three years) of methylprednisolone in 25 cats detected an increase of triglycerides, amylase and monocytes, yet changes remained within the reference interval. 87 Recommendations Systemic glucocorticoids are rapid and effective in most cats with FASS (QOE 1; SOR A). Treatment with 1.4-1.5 mg/kg once daily of methylprednisolone-induced remission in 33 of 36 cats within 14 days.…”

Section: Systemic Glucocorticoidsmentioning

confidence: 99%

See 1 more Smart Citation

Treatment of the feline atopic syndrome – a systematic review

Mueller¹,

Nuttall

Prost

et al. 2021

Veterinary Dermatology

View full text Add to dashboard Cite

Background-Feline allergic skin disease and asthma occur regularly in small animal practice. Objectives-To provide evidence-based recommendations for small animal practitioners on the treatment of feline atopic syndrome (FAS). Methods and materials-The authors reviewed the literature available before February 2020, prepared a detailed evidence-based literature review and made recommendations based on the evaluated evidence. Results-Sixty-six papers and abstracts were identified describing treatment interventions for FAS and evaluated to establish treatment recommendations. For many treatment options, the papers were retrospective, open studies or case reports. Conclusion and clinical relevance-In this review, there was good evidence for the efficacy of systemic glucocorticoids and ciclosporin, and limited evidence for the efficacy of topical glucocorticoids, oclacitinib and allergenspecific immunotherapy in feline atopic skin syndrome. Evidence pointed to low-to-moderate efficacy for antihistamines, fatty acids and palmitoyl ethanolamide. In feline asthma, there was good evidence for the efficacy of oral and inhaled glucocorticoids, and limited evidence of moderate efficacy for allergen-specific immunotherapy. Evidence supported low-to-moderate efficacy of mesenchymal stem cells, inhaled lidocaine and oclacitinib as treatments for feline asthma. For almost all therapeutic options (with the exception of glucocorticoids and ciclosporin), more randomised controlled trials are needed.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Systemic Glucocorticoidsmentioning

confidence: 99%

Treatment of the feline atopic syndrome – a systematic review

Mueller¹,

Nuttall

Prost

et al. 2021

Veterinary Dermatology

View full text Add to dashboard Cite

show abstract

“…The literature describing hyperadrenocorticism in cats is scarce, with most studies describing case series or case reports (LOE 5) 251–266 . Some reports included necropsy results or the findings of CT or abdominal ultrasound imaging, but none were focused on identifying thrombosis.…”

Section: Peco Question: Hyperadrenocorticism (Cats)mentioning

confidence: 99%

2022 Update of the Consensus on the Rational Use of Antithrombotics and Thrombolytics in Veterinary Critical Care (CURATIVE) Domain 1‐ Defining populations at risk

deLaforcade

Bacek

Blais

et al. 2022

J Vet Emergen Crit Care

View full text Add to dashboard Cite

Objectives: To expand the number of conditions and interventions explored for their associations with thrombosis in the veterinary literature and to provide the basis for prescribing recommendations. Design: A population exposure comparison outcome format was used to represent patient, exposure, comparison, and outcome. Population Exposure Comparison Outcome questions were distributed to worksheet authors who performed comprehensive searches, summarized the evidence, and created guideline recommendations that were reviewed by domain chairs. The revised guidelines then underwent the Delphi survey process to reach consensus on the final guidelines. Diseases evaluated in this iteration included heartworm disease (dogs and cats), immune-mediated hemolytic anemia (cats), protein-losing nephropathy (cats), protein-losing enteropathy (dogs and cats), sepsis (cats), hyperadrenocorticism (cats), liver disease (dogs), congenital portosystemic shunts (dogs and cats) and the following interventions: IV catheters (dogs and cats), arterial catheters (dogs and cats), vascular access ports (dogs and cats), extracorporeal circuits (dogs and cats) and transvenous pacemakers (dogs and cats).Results: Of the diseases evaluated in this iteration, a high risk for thrombosis was defined as heartworm disease or protein-losing enteropathy. Low risk for thrombosis was defined as dogs with liver disease, cats with immune-mediated hemolytic anemia, protein-losing nephropathy, sepsis, or hyperadrenocorticism. Conclusions:Associations with thrombosis are outlined for various conditions and interventions and provide the basis for management recommendations. Numerous knowledge gaps were identified that represent opportunities for future studies.

show abstract

“…Oral administration of tablet‐type medications, more so than liquid formulations, can be challenging in feline patients, which can decrease compliance and result in lack of disease control 13 . Parenteral glucocorticoids are commonly utilised for patients with feline HD that are difficult to medicate orally, and their use may be associated with an increased risk of acute‐onset congestive heart failure 14–17 …”

Section: Introductionmentioning

confidence: 99%

“…13 Parenteral glucocorticoids are commonly utilised for patients with feline HD that are difficult to medicate orally, and their use may be associated with an increased risk of acute-onset congestive heart failure. [14][15][16][17] At this time, there are no registered oral liquid glucocorticoids for the treatment of feline HD in the United States. Commercial compounding pharmacies offer oral glucocorticoid liquid formulations with various flavours for cats.…”

Section: Introductionmentioning

confidence: 99%

Oral dexamethasone sodium phosphate solution significantly reduces pruritus and clinical lesions in feline hypersensitivity dermatitis: an open‐label study

McClintock

Austel

Gogal

et al. 2021

Veterinary Dermatology

View full text Add to dashboard Cite

Background There are no liquid oral glucocorticoids labelled for management of pruritus and clinical lesions of feline hypersensitivity dermatitis (feline HD). Hypothesis First, to demonstrate that dexamethasone sodium phosphate (DexSP, DexajectSP, Henry Schein; Dublin, OH, USA; 4 mg/mL), an intravenous glucocorticoid, can be absorbed by healthy cats when administered orally. Second, to demonstrate the efficacy of orally administered DexSP for reducing pruritus and clinical lesions in patients with feline HD. Animals Seven healthy and 12 client‐owned cats with HD. Methods and materials Healthy cats were administered a single dose of 0.2 mg/kg DexSP p.o. and serum concentrations were measured using enzyme‐linked immunosorbent assay (ELISA). Feline HD patients were assessed with SCORing Feline Allergic Dermatitis (SCORFAD) and pruritus Visual Analog Scale (pVAS) at Visit 1 (V1) and after 20–31 days of receiving 0.2 mg/kg/day DexSP p.o. (V2). Complete blood cell counts, serum chemistry profile, and urinalysis were performed in 50% of feline HD patients at both visits. Results Healthy cats had detectable serum concentrations of DexSP following oral administration; concentrations ranged from 0.7 to 92.3 ng/mL. Feline HD patients showed significant decreases in SCORFAD and pVAS scores from V1 to V2. Conclusions DexSP was absorbed when administered orally to healthy cats and 0.2 mg/kg/day DexSP is an efficacious dose to rapidly improve the pruritus and clinical lesions associated with feline HD.

show abstract

Retrospective Study on the Effects of Long-Term Use of Methylprednisolone Acetate on the Blood Work of 25 Cats

Cited by 4 publications

References 17 publications

Treatment of the feline atopic syndrome – a systematic review

Treatment of the feline atopic syndrome – a systematic review

2022 Update of the Consensus on the Rational Use of Antithrombotics and Thrombolytics in Veterinary Critical Care (CURATIVE) Domain 1‐ Defining populations at risk

Oral dexamethasone sodium phosphate solution significantly reduces pruritus and clinical lesions in feline hypersensitivity dermatitis: an open‐label study

Contact Info

Product

Resources

About